Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Is the company's stock about to start losing weight?

Buy Gilead Sciences Real Money Pro($)

Its prospects exploded with a breakthrough drug.
For speculative investors.
The CEO of Allergan has created value for shareholders.

Shotgun Investing in Biotech Real Money Pro($)

Two speculative plays are worthy of consideration.

The Fibocall: Celgene Real Money Pro($)

This beloved stock has triggered a long-term overbought signal again.

Invest in a Healthy Liver Real Money Pro($)

Drugs for liver diseases are good opportunities.
Some growth leaders in the sector are getting technical support.
Try the Peter Lynch technique in picking stocks.

Columnist Conversations

Monitise has announced the sale of additional stock to Telefonica, Santander and Master Card. Expands relation...
Lights, Camera, ACTION! This move lately in GPRO has been stellar, up nearly 12% over the past couple of sess...
For just under two weeks MCD has been bumping up against a very solid wall of resistance. The $96.95 to ...
Texas Instruments is surging today. Shares are up over 2.7% and are moving further into new 52W high gro...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.